Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity
- PMID: 16625206
- DOI: 10.1038/nature04721
Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity
Abstract
A common viral immune evasion strategy involves mutating viral surface proteins in order to evade host neutralizing antibodies. Such immune evasion tactics have not previously been intentionally applied to the development of novel viral gene delivery vectors that overcome the critical problem of anti-vector immunity. Recombinant, replication-incompetent adenovirus serotype 5 (rAd5) vector-based vaccines for human immunodeficiency virus type 1 and other pathogens have proved highly immunogenic in preclinical studies but will probably be limited by the high prevalence of pre-existing anti-Ad5 immunity in human populations, particularly in the developing world. Here we show that rAd5 vectors can be engineered to circumvent anti-Ad5 immunity. We constructed novel chimaeric rAd5 vectors in which the seven short hypervariable regions (HVRs) on the surface of the Ad5 hexon protein were replaced with the corresponding HVRs from the rare adenovirus serotype Ad48. These HVR-chimaeric rAd5 vectors were produced at high titres and were stable through serial passages in vitro. HVR-chimaeric rAd5 vectors expressing simian immunodeficiency virus Gag proved comparably immunogenic to parental rAd5 vectors in naive mice and rhesus monkeys. In the presence of high levels of pre-existing anti-Ad5 immunity, the immunogenicity of HVR-chimaeric rAd5 vectors was not detectably suppressed, whereas the immunogenicity of parental rAd5 vectors was abrogated. These data demonstrate that functionally relevant Ad5-specific neutralizing antibodies are focused on epitopes located within the hexon HVRs. Moreover, these studies show that recombinant viral vectors can be engineered to circumvent pre-existing anti-vector immunity by removing key neutralizing epitopes on the surface of viral capsid proteins. Such chimaeric viral vectors may have important practical implications for vaccination and gene therapy.
Comment in
-
Vaccines: engineering immune evasion.Nature. 2006 May 11;441(7090):161. doi: 10.1038/441161a. Nature. 2006. PMID: 16688158 Free PMC article.
Similar articles
-
Designed recombinant adenovirus type 5 vector induced envelope-specific CD8(+) cytotoxic T lymphocytes and cross-reactive neutralizing antibodies against human immunodeficiency virus type 1.J Gene Med. 2009 Feb;11(2):139-49. doi: 10.1002/jgm.1277. J Gene Med. 2009. PMID: 19065543
-
An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity.Vaccine. 2004 Aug 13;22(23-24):3035-44. doi: 10.1016/j.vaccine.2004.02.011. Vaccine. 2004. PMID: 15297053
-
Chimeric adenovirus type 5/35 vector encoding SIV gag and HIV env genes affords protective immunity against the simian/human immunodeficiency virus in monkeys.Virology. 2007 Oct 25;367(2):390-7. doi: 10.1016/j.virol.2007.06.012. Epub 2007 Jul 12. Virology. 2007. PMID: 17628628
-
Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors.Expert Opin Biol Ther. 2009 Dec;9(12):1521-31. doi: 10.1517/14712590903307388. Expert Opin Biol Ther. 2009. PMID: 19780714 Review.
-
Immune responses to gene therapy vectors: influence on vector function and effector mechanisms.Gene Ther. 2004 Oct;11 Suppl 1:S10-7. doi: 10.1038/sj.gt.3302364. Gene Ther. 2004. PMID: 15454952 Review.
Cited by
-
Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.Front Immunol. 2022 Oct 13;13:1012806. doi: 10.3389/fimmu.2022.1012806. eCollection 2022. Front Immunol. 2022. PMID: 36311790 Free PMC article. Review.
-
Development of an Ad5H3 Chimera Using the "Antigen Capsid-Incorporation" Strategy for an Alternative Vaccination Approach.Open Virol J. 2016 Apr 26;10:10-20. doi: 10.2174/1874357901610010010. eCollection 2016. Open Virol J. 2016. PMID: 27335626 Free PMC article.
-
Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adapters.Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):E869-77. doi: 10.1073/pnas.1213653110. Epub 2013 Feb 19. Proc Natl Acad Sci U S A. 2013. PMID: 23431166 Free PMC article.
-
Native and engineered tropism of vectors derived from a rare species D adenovirus serotype 43.Oncotarget. 2016 Aug 16;7(33):53414-53429. doi: 10.18632/oncotarget.10800. Oncotarget. 2016. PMID: 27462785 Free PMC article.
-
Disrupted adenovirus-based vaccines against small addictive molecules circumvent anti-adenovirus immunity.Hum Gene Ther. 2013 Jan;24(1):58-66. doi: 10.1089/hum.2012.163. Epub 2012 Dec 21. Hum Gene Ther. 2013. PMID: 23140508 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources